Trials of the effects of drugs and hormones on lipids and lipoproteins

Wa, Mann; Windler, E; Bao-quan, FU; Greten, H.

doi:10.1097/00041433-199512000-00004

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past few years numerous studies have shown the efficacy and safety of 4 HMG-CoA reductase inhibitors currently available: lovastatin, simvastatin, pravastatin, and fluvastatin, A reduction of total cholesterol ranging from 23-45% (mean 30%) can be achieved, due to a 26-42% (mean 35%) reduction of LDL-cholesterol. This effect is accompanied by a 11-32% (mean 20%) decrease in serum triglycerides and a 8-13% (mean 8%) increase of HDL-cholesterol [47,48]. Some reports have shown an increase in lipoprotein(a) [Lp(a)] levels during treatment with the statins, ranging from 8-12% [30,37,49], On a milligram basis simvastatin is twice as potent as pravastatin and lovastatin, and 4 times as potent as fluvastatin [50,51].…”

Section: L Hmg-coa Reductase Inhibitorsmentioning

confidence: 97%

LDL-cholesterol lowering and atherosclerosis - clinical benefit and possible mechanisms: an update

Stalenhoef

1997

The Netherlands Journal of Medicine

View full text Add to dashboard Cite

The results of several lipid-lowering randomized trials have been released during the past years and have confirmed the lipid hypothesis. Reduction of cholesterol by potent drugs in clinically symptomatic or asymptomatic patients with above-average cholesterol levels will substantially reduce the risk of coronary events. The present article gives a review of potent low-density lipoprotein cholesterol-lowering treatments and discusses developments in hypolipidaemic therapy in relation to recent primary and secondary prevention studies. In addition, possible mechanisms of cholesterol lowering in retardation of the atherosclerotic process are summarised. © 1997 Elsevier Science B.V.

show abstract

Section: L Hmg-coa Reductase Inhibitorsmentioning

confidence: 97%

LDL-cholesterol lowering and atherosclerosis - clinical benefit and possible mechanisms: an update

Stalenhoef

1997

The Netherlands Journal of Medicine

View full text Add to dashboard Cite

show abstract

Infusion Nanoelectrospray Ionization Mass Spectrometry

Henion¹

2012

Encyclopedia of Drug Metabolism and Interactions

View full text Add to dashboard Cite

This report reviews the introductory aspects of electrospray ionization coupled with mass spectrometry and highlights those aspects of electrospray that play an important role in its application to analyzing real‐world samples. Following a discussion of matrix effects, factors that affect analyte response and sensitivity, and the flow rate factors of the spray solvent, the relative benefits of on‐line HPLC or UPLC are contrasted with an infusion electrospray sample introduction approach, which, of course, precludes any aspects of chromatographic separation. The introduction of samples via infusion bypasses the need for a chromatographic system, including its pumps, autosampler, separation column, and the compromise of a mobile phase, which must accomplish the chromatographic separation while also allowing the electrospray ionization process to occur. Thus, infusion sample introduction is in principle much easier to accomplish. However, there are clear benefits to employing HPLC for the analysis of complex samples. So, how can infusion sample introduction be worthwhile? It can be worthwhile because nanoelectrospray, or electrospray at 20–500 nL/min solvent flow rates, provides some unique benefits over the higher flow rate regime that has been customarily used. Thus, nanoelectrospray provides improved sensitivity, reduced matrix suppression, and normalized response from differing analytes and conserves precious samples if this is an issue. This review overviews these principles and provides several successful examples of published work where infusion nanoelectrospray experiments have merit.

show abstract